The Western Blot HIV Test: Its Role in Diagnosis

The Western blot served for roughly three decades as the standard confirmatory test for HIV infection, used to verify a positive screening result before a diagnosis was finalized. In the United States, it was formally removed from the recommended diagnostic algorithm in 2014, replaced by newer assays that detect infection sooner and handle ambiguous results more reliably. Yet the test remains in use in many countries and clinical settings worldwide, and understanding what it does, where it falls short, and why it was eventually sidelined tells you a lot about how HIV testing has evolved.

How the Western Blot Works in HIV Testing

A Western blot separates the individual proteins of a virus by size. Viral proteins are broken apart, coated with a charge so they migrate through a gel in an electric field according to their molecular weight, and then transferred onto a membrane strip. That strip is exposed to the patient’s blood serum. If the patient’s immune system has made antibodies against HIV, those antibodies bind to the corresponding viral proteins on the strip, producing visible bands at specific locations.

Each band corresponds to a known HIV protein. The three main categories are envelope proteins (like gp160, gp120, and gp41), polymerase proteins (like p66, p51, and p31), and core proteins (like p55, p24, and p17). A trained technician reads the strip and determines which bands are present. The pattern of bands drives the interpretation: positive, negative, or indeterminate.

What Counts as a Positive Result

There has never been a single universal rule for reading a Western blot. Different organizations developed different criteria for what band pattern qualifies as positive, and these criteria varied enough to matter in practice. The CDC, the World Health Organization, the American Red Cross, and other bodies each published their own interpretive standards.

In a study of Ethiopian blood samples that gave discordant screening results, about 13% displayed reactivity to certain protein combinations that would have been called positive under CDC criteria but not under stricter WHO criteria. Using CDC rules, roughly 19% of those would have been falsely positive, compared with about 7% under WHO rules.

1PubMed Central. Indeterminate human immunodeficiency virus Western blot profiles in ethiopians with discordant screening-assay results

This variation in interpretive criteria was a recognized problem. A CDC performance evaluation program found that laboratories enrolled in the program reported Western blot results using inconsistent criteria, meaning two labs could look at the same strip and reach different conclusions.

2PubMed. Interpretive criteria used to report western blot results for HIV-1-antibody testing–United States

When a result is clearly positive, envelope proteins tend to dominate. In one analysis of confirmed HIV-positive samples, gp160 appeared on every single reactive strip. All three envelope proteins showed up together in about 97% of cases, and all three polymerase proteins in about 93%. The core protein group was the least consistent, present in roughly 72% of reactive samples. The band most likely to be missing was p31, absent in about 7% of confirmed positive cases.

3PubMed. Western blot profile in HIV infection

The Indeterminate Problem

One of the Western blot’s biggest headaches was the indeterminate result: a strip showing some bands but not enough to meet the threshold for positive. This left clinicians and patients in limbo. An indeterminate result could mean early infection (the immune system has started producing some antibodies but not yet the full set), cross-reacting antibodies from another condition, or a technical artifact on the strip.

Autoimmune diseases are a well-known source of false-positive screening tests and indeterminate Western blots. In a documented case of systemic lupus erythematosus, the initial screening ELISA came back positive for HIV, while the Western blot was negative, ultimately confirming that the screening result was a false alarm caused by autoantibodies.

4IOS Press (Technology and Health Care). Systemic lupus erythematosus patient with false positive results of antibody to HIV: A case report and a comprehensive literature review

That case illustrates the Western blot doing exactly what it was designed to do: catching a false positive from the screening step. But when the blot itself returns an indeterminate result, the standard advice was to wait several weeks and retest, which introduced anxiety, delay, and the risk that patients would not come back.

The most common cause of indeterminate patterns in low-risk populations was isolated reactivity to the p24 band, accounting for about 30% of indeterminate results in the Ethiopian study mentioned earlier.

1PubMed Central. Indeterminate human immunodeficiency virus Western blot profiles in ethiopians with discordant screening-assay results

The Traditional Two-Test Algorithm and Why It Changed

For years, HIV diagnosis in the United States followed a straightforward two-step process. A patient’s blood was first screened with an enzyme immunoassay (commonly called ELISA). If the screen was reactive, it was repeated. If still reactive, the sample went to a Western blot for confirmation. Only when both tests agreed was a diagnosis of HIV infection made.

5PubMed Central. Human Immunodeficiency Virus Diagnostic Testing: 30 Years of Evolution

This algorithm worked reasonably well when the goal was to confirm established infections. The problem was timing. The Western blot detects antibodies, and the body needs time to produce enough of them for the test to pick up. Fourth-generation combination assays, which detect both HIV antibodies and the p24 antigen (a viral protein that shows up earlier than antibodies), can flag an infection days to weeks before the Western blot turns positive.

6Elsevier (Journal of Clinical Virology). Performance evaluation of the Bio-Rad Laboratories GS HIV Combo Ag/Ab EIA, a 4th generation HIV assay for the simultaneous detection of HIV p24 antigen and antibodies to HIV-1 (groups M and O) and HIV-2 in human serum or plasma

One large modeling study estimated that the Western blot becomes positive a median of 25 days after the earliest RNA-based assay can detect HIV, while the newest antigen/antibody combination tests close that gap to about 6 days.

7Clinical Infectious Diseases. Time Until Emergence of HIV Test Reactivity Following Infection With HIV-1: Implications for Interpreting Test Results and Retesting After Exposure

That roughly three-week delay matters enormously. A person with acute HIV has extremely high viral loads and is highly infectious. Missing them during that window is a public health problem, not just a diagnostic inconvenience.

The updated U.S. algorithm, recommended by the CDC and the Association of Public Health Laboratories starting in 2014, begins with a fourth-generation antigen/antibody combination immunoassay. If that is reactive, the next step is an HIV-1/HIV-2 antibody differentiation assay rather than a Western blot. If results are discordant or ambiguous, an HIV-1 RNA test (nucleic acid amplification) settles the question. The Western blot does not appear anywhere in this updated pathway. This newer approach can identify acute infections, differentiate between HIV-1 and HIV-2, and resolve ambiguous results faster than the old method.

Despite this shift, many clinicians globally continue to rely on the ELISA-Western blot scheme for diagnosis.

8IDCases. Near misdiagnosis of acute HIV-infection with ELISA-Western Blot scheme: Time for mindset change

The HIV-2 Cross-Reactivity Issue

The Western blot was designed primarily around HIV-1 proteins. HIV-2, which is less common globally but prevalent in parts of West Africa and occasionally seen elsewhere, shares enough protein structure with HIV-1 that antibodies to HIV-2 can light up bands on an HIV-1 Western blot strip. In one evaluation, all four confirmed HIV-2 samples tested showed three or four bands on the HIV-1 Western blot, with three of the four being classified as HIV-1 positive and one as indeterminate.

9PubMed Central. Clinical performance of the Multispot HIV-1/HIV-2 rapid test to correctly differentiate HIV-2 from HIV-1 infection in screening algorithms using third and fourth generation assays and to identify cross reactivity with the HIV-1 Western Blot

The consequence is that an HIV-2 infection could be misidentified as HIV-1 based on the Western blot alone. This distinction matters for treatment: certain antiretroviral drugs effective against HIV-1 do not work well against HIV-2. The newer diagnostic algorithms address this by using differentiation assays that separately detect antibodies specific to each virus type, something the HIV-1 Western blot was never designed to do.

Diagnosing Infants Born to HIV-Positive Mothers

One of the starkest limitations of any antibody-based test, the Western blot included, shows up in newborns. Babies born to HIV-infected mothers carry maternal antibodies transferred across the placenta during pregnancy. These maternal antibodies can persist for up to 18 months, meaning a standard ELISA or Western blot can come back positive in an infant who is not actually infected.

10PubMed Central. Problems in Diagnosis of HIV Infection in Babies

For infants younger than 18 months, diagnosis requires tests that detect the virus itself rather than antibodies to it, typically HIV DNA or RNA assays. After 18 months, when maternal antibodies have cleared, the standard serological methods including the Western blot become reliable.

11PubMed. Pediatric HIV infection: diagnostic laboratory methods

When Antibodies Disappear After Early Treatment

An unusual clinical scenario further complicates the Western blot’s role. When someone is diagnosed with HIV during acute infection, very early in the course, and begins antiretroviral therapy immediately, the immune system sometimes never fully develops the broad antibody response that would produce a classic positive Western blot pattern. In some cases, antibody levels can actually decline to the point where previously positive tests become negative, a phenomenon called seroreversion.

In one cohort of 87 people treated during acute or early infection, about 7% experienced seroreversion on at least one antibody assay over a median follow-up of about 90 weeks.

12PubMed. Seroreversion in subjects receiving antiretroviral therapy during acute/early HIV infection

In another report, three patients who started treatment within days of their initial presentation never developed a fully evolved HIV-1 antibody response and showed complete or partial seroreversion over roughly four years of follow-up, even though their immune responses to other viruses remained intact.

13PubMed. Incomplete HIV type 1 antibody evolution and seroreversion in acutely infected individuals treated with early antiretroviral therapy

This is not the antibodies “curing” the infection. The virus is still present, suppressed by medication. But if one of these patients were tested with a Western blot alone, the result could be negative or indeterminate despite confirmed HIV infection. It is an edge case, but it underscores why relying on antibody detection alone has blind spots, particularly as treatment guidelines increasingly push toward starting therapy as early as possible.

Subjectivity in Reading the Strips

Unlike modern automated assays that output a number or a signal-to-cutoff ratio, the Western blot depends on a human eye interpreting bands on a membrane. Whether a faint band is “present” or “absent” can vary from reader to reader and lab to lab. Quality assessment data have shown that variability in subjectively read HIV assays ranged from about 1% to over 8% between readers, depending on the assay type. For Western blots specifically, results that differed from the reference reading were observed in roughly 5% of quality assessment panels.

14Elsevier. Standardisation of subjectively scored HIV immunoassays: developing a quality assurance program to assist in reproducible interpretation of results using an anti-HIV particle agglutination assay as a model

Five percent might sound small, but scaled across millions of tests annually worldwide, that translates into a meaningful number of discrepant results. Automated assays eliminate this layer of human judgment, which is one more reason the field has moved away from the Western blot in settings where newer tests are available.

Dried Blood Spots and Non-Clinical Settings

As HIV testing expanded beyond traditional clinics into community health fairs, mobile units, and other non-clinical venues, the Western blot presented a practical challenge: it requires a proper blood draw, cold-chain transport, and a well-equipped laboratory. To bridge this gap, some programs began using dried blood spots, which are exactly what they sound like: drops of blood collected on filter paper, dried, and mailed to a lab.

In one program that evaluated this approach over about two years, roughly 85% of dried blood spot samples sent for Western blot confirmation came back positive, compared with about 79% of standard venous blood samples sent during the same period. The indeterminate rate was similar between the two methods, around 1.4% for dried blood spots and 1.7% for venous specimens.

15Elsevier. Expansion of HIV screening to non-clinical venues is aided by the use of dried blood spots for Western blot confirmation

The higher positivity rate in dried blood spots likely reflects the populations being tested and the screening context rather than any difference in the test’s performance. But the takeaway is that the Western blot can be adapted to remote or non-clinical settings with reasonable reliability when no alternative confirmatory method is available.

Rapid Tests and the Global Shift Away From the Western Blot

In resource-limited settings, the Western blot was always a luxury. The equipment, trained personnel, and turnaround time it requires are poorly suited to clinics that may lack reliable electricity. Rapid diagnostic tests, which can be performed at the point of care with a finger-prick blood sample and read in minutes, have largely replaced both the ELISA-Western blot combination and stand-alone Western blot confirmation in many parts of the world.

A meta-analysis evaluating blood-based rapid tests concluded that the accumulated evidence supports using rapid tests not only for screening but potentially as a replacement for the confirmatory Western blot step, allowing same-day diagnosis and linkage to treatment.

16PubMed Central. Evaluation of Blood-Based Antibody Rapid Testing for HIV Early Therapy: A Meta-Analysis of the Evidence

Instrument-free testing strategies combining rapid screening assays with particle agglutination tests have also been evaluated as efficient alternatives, though their cost remains a consideration.

17Journal of Acquired Immune Deficiency Syndromes. Diagnosis of HIV Infection With Instrument-Free Assays as an Alternative to the ELISA and Western Blot Testing Strategy

The overall trajectory is clear: the Western blot, while historically important and still capable of doing what it was designed to do, has been outpaced by faster, cheaper, and more automated technologies. Where it remains in use, it is typically because the infrastructure or regulatory frameworks have not yet caught up with the newer algorithms. For the patient, the practical impact of this shift is straightforward: faster answers, fewer ambiguous results, and earlier detection of infection when it matters most.

When You Might Still Encounter a Western Blot

If you are tested for HIV in the United States or Western Europe today, you are unlikely to encounter a Western blot. The updated algorithms using combination antigen/antibody assays and differentiation immunoassays are now standard in most large laboratories. But there are circumstances where a Western blot might still appear in your medical experience.

Some smaller or rural laboratories may not have transitioned to the newer algorithm. In countries where regulatory frameworks still mandate the ELISA-Western blot sequence, the test remains the confirmatory standard. Research settings occasionally use the Western blot to characterize antibody responses in detail, since the band pattern provides more granular information about which viral proteins the immune system is targeting. And older medical records from before 2014 will reference Western blot results, which can matter if you are reviewing a patient’s diagnostic history.

If you do receive a Western blot result, the key thing to know is that a clearly positive result with multiple strong bands across envelope, polymerase, and core protein categories is highly reliable. A clearly negative result with no bands is equally reliable. The trouble zone is the indeterminate result, where some bands appear but not enough to meet the threshold, and for that, the correct next step is additional testing with a different method rather than simply repeating the blot. The newer diagnostic algorithms were designed precisely to shrink that ambiguous middle ground.